myhrcat/iStock via Getty Images
Investment thesis
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) has been on my radar for quite a while now, and after close observation, I think now is a good time to dive in. The stock
Tonix Pharmaceuticals: Big Risk, Bigger Reward - Initiating With A Buy
Summary
- I'm initiating Tonix Pharmaceuticals Holding Corp. with a Buy rating, eyeing a rally on potential FDA approval for flagship drug Tonmya in August.
- Tonmya targets fibromyalgia, a large, underserved market; the FDA decision is due August 15th, and approval could dramatically boost Tonix's revenue.
- Tonix has its work cut out for it, but I'm a firm believer that they could have a first-mover advantage in this market.
- The stock traded down 24% last week before slightly recovering, and I see this as a window to jump in ahead of August.
- I hereon share my sentiment on TNXP stock and why I see more upside ahead.
I’m a retired Wall Street PM specializing in TMT; since kickstarting my career, I’ve spent over two decades in the market navigating the technology landscape, focusing on risk mitigation through the dot com bubble, credit default of ‘08, and, more recently, with the AI boom. In one word, what I’d like my service to revolve around is momentum.
Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.